Trial reportBreast cancer research and treatment2025
Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens.
Trial report in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04722718 (Efficacy and Safety of Neoadjuvant Therapy With Sintilimab and Apatinib Combined Chemotherapy in Triple-negative Breast Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Neoadjuvant Therapy With Sintilimab and Apatinib Combined Chemotherapy in Triple-negative Breast Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdding immunotherapy to chemotherapy can modestly improve the pathological complete response (pCR) rate in triple-negative breast cancer (TNBC), while our previous NeoSAC study demonstrated that combining anti-angiogenic therapy can further enhance pCR. However, research on the mechanisms underlying the efficacy differences and biomarker comparisons across these treatment regimens remains insufficient. PATIENTS AND
methodsFemale TNBC patients were consecutively enrolled into three groups: chemotherapy (chemo), chemo-immunotherapy (chemo-ICI), and chemo-immunotherapy-anti-angiogenesis (chemo-ICI-AA, from our NeoSAC study, NCT04722718). Efficacy and safety were compared, with RNA sequencing and immune microenvironment analyses conducted to explore mechanisms of efficacy differences and identify potential biomarkers.
resultsThe total pCR rates in the chemo, chemo-ICI, and chemo-ICI-AA groups were 43.3%, 60.0%, and 72.7%, respectively. Baseline immune profiles were similar across groups, with comparable stromal, immune, and GEP scores. In the chemo-ICI-AA group, higher CD8 + T cells, TH1 cells, and TIL infiltration in pCR patients suggested their potential as biomarkers. Enhanced cytolytic activity, pro-inflammatory pathways, T-cell costimulation, and oxeiptosis correlated with higher pCR rates in the chemo-ICI-AA group. Notably, oxeiptosis has emerged as a potential predictor of treatment response, especially in pCR patients from the chemo-ICI and chemo-ICI-AA groups. Additionally, ALK (p = 0.017) and ATP6V1C2 (p = 0.036) were identified as significant genes in the chemo-ICI-AA pCR group, with predictive value for pCR outcomes.
conclusionAdding immunotherapy and anti-angiogenic therapy to chemotherapy progressively increased the pCR rate. We emphasized the critical role of differentially expressed genes and immune microenvironment changes in predicting treatment outcomes.
Indexed as
Identifiers
40864333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.